Clinical trial
Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial)
NCT02348723 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 28, 2015
- Completion date
- November 14, 2016
- Enrollment
- 678 (actual)
- Sites
- 87
Conditions
As the registry lists them; a condition with its own page is linked.